Brian Culley, Lineage Cell Therapeutics CEO

Lin­eage Cell Ther­a­peu­tics opens new Cal­i­for­nia R&D fa­cil­i­ty and ex­pands Is­rael man­u­fac­tur­ing site

Last year, Roche and Genen­tech paid $50 mil­lion for li­cens­ing rights to Lin­eage Cell Ther­a­peu­tics’ OpRe­gen pro­gram, a cell ther­a­py that looks to re­gen­er­ate healthy ver­sions of reti­nal pig­ment ep­ithe­lial cells in pa­tients’ eyes.

Now the biotech is grow­ing its phys­i­cal pres­ence with a new fa­cil­i­ty in the US and an ex­pan­sion in Is­rael.

Lin­eage has opened the doors to a 12,000-square-foot R&D fa­cil­i­ty in Carls­bad, CA, and an­nounced an ex­pan­sion to its GMP man­u­fac­tur­ing fa­cil­i­ty in Jerusalem. The ex­pan­sion in Is­rael will al­low for the de­vel­op­ment of more large-scale man­u­fac­tur­ing process­es and the con­tin­ued sup­ply of ma­te­ri­als nec­es­sary for the Phase I/II of OpRe­gen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.